Cohort Study: Sulfonylureas as Second Line Drugs in Type 2 Diabetes and the Risk of Adverse Outcomes

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study – The BMJ (free)

Editorial: Sulfonylureas as second line treatment for type 2 diabetes – The BMJ (free for a limited period)

Commentaries: Diabetes: Switching to Sulfonylureas from Metformin Linked to Increased Side Effects – MedicalResearch.com (free) AND Switching diabetes patients to sulfonylurea linked with complications – Pulse (free) AND Raised risk of MI and mortality when starting sulfonylurea – OnMedica (free)